Tatva Chintan Pharma Chem Share Price Today (TATVA)
TODAY IN ONE LINE
TATVA surged 6.4% on above-average volume (5.0x avg), outperforming Nifty's 0.3% move, supported by recent strong earnings.
With a market cap of ₹4,174.31 Cr., it trades at a P/E of 76.19. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Tatva Chintan Pharma Chem flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 907.5% YoY
- ●Quarterly OutperformanceLatest quarter Sales up 43.0% and Profit up 155.0%
- ●Healthy Operating MarginsOPM is structurally strong at 19.4%
- ●High Promoter HoldingPromoters hold 72.0% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Poor Capital ReturnsLow ROE of 5.5%
- ●Expensive ValuationTrading at a high P/E ratio of 66.2x
- ●Rising Receivables vs SalesReceivables grew 23.2% outpacing sales growth of -2.7%
Latest Tatva Chintan Pharma Chem News
What changed recently?
Recent events, corporate actions, and announcements.
Tatva Chintan Pharma Chem Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Tatva Chintan Pharma Chem Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Tatva Chintan Pharma Chem Ltd trades at a P/E of 76.19× and P/B of 5.01×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Tatva Chintan Pharma Chem Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Tatva Chintan Pharma Chem Ltd — derived from the live tape, not yesterday's close.
Tatva Chintan Pharma Chem Ltd last traded at ₹1,788.2 with an intraday range of ₹1,676.1–₹1,799 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹1788.20| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 2078.57 | +290.37 | +16.24% |
| R3 | 1955.67 | +167.47 | +9.37% |
| R2 | 1877.33 | +89.13 | +4.98% |
| R1 | 1832.77 | +44.57 | +2.49% |
| PIVOT | 1754.43 | -33.77 | -1.89% |
| CURRENT | 1788.20 | — | — |
| S1 | 1709.87 | -78.33 | -4.38% |
| S2 | 1631.53 | -156.67 | -8.76% |
| S3 | 1586.97 | -201.23 | -11.25% |
| S4 | 1464.07 | -324.13 | -18.13% |
TATVA is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹1676.1–₹1735
Trading Above opening range, showing Bullishness
Tatva Chintan Pharma Chem Ltd financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Tatva Chintan Pharma Chem Ltd — consolidated or standalone — with margins, YoY growth and key ratios inline.
Tatva Chintan Pharma Chem Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹4,174.31 Cr. and reported EPS of ₹22.00.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 383 | 506 ▲ 32.2% |
| Sales Growth YoY %Derived | -2.74% | 32.18% |
| Other Income | 2 | 4 ▲ 53.3% |
| Total Income | 385 | 509 ▲ 32.3% |
| 199 | 225 ▲ 12.9% | |
| Gross ProfitDerived | 184 | 281 ▲ 53.1% |
| Gross Margin %Derived | 48.02% | 55.61% |
| 150 | 188 ▲ 25.8% | |
| EBITDA (Operating Profit)Derived | 34 | 93 ▲ 172.3% |
| OPM %Derived | 8.94% | 18.42% |
| 29 | 40 ▲ 37.1% | |
| Profit Before Tax (PBT) | 8 | 57 ▲ 652.2% |
| 2 | 15 ▲ 701.4% | |
| Effective Tax %Derived | 24.62% | 26.23% |
| Total Profit for Period | 6 | 42 ▲ 636.1% |
| Net Profit (Owner's PAT)Derived | 6 | 42 ▲ 636.1% |
| Net Profit Margin %Derived | 1.49% | 8.31% |
| PAT Growth YoY %Derived | -81.18% | 636.11% |
| Earnings Per Share (EPS ₹) | 2.44 | 17.98 ▲ 636.9% |
| Diluted Shares Outstanding (Cr) | 2 | 2 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | 1 | 3 ▲ 355.4% |
| Total Expenses (incl. D&A & Interest) | 377 | 452 ▲ 19.9% |
| Material Cost % of RevenueDerived | 45.40% | 51.94% |
| Employee Cost % of RevenueDerived | 13.83% | 12.44% |
| Other Cost % of RevenueDerived | 25.25% | 24.76% |
| Interest Coverage (x)Derived | 5.08x | 19.75x |
| Period | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|
| Revenue from Operations | 434 | 424 ▼ 2.3% | 394 ▼ 7.1% | 383 ▼ 2.7% | 506 ▲ 32.2% | |
| Sales Growth YoY %Derived | — | -2.31% | -7.11% | -2.74% | 32.18% | |
| Other Income | 9 | 6 ▼ 35.4% | 8 ▲ 30.7% | 2 ▼ 69.2% | 4 ▲ 53.3% | |
| Total Income | 443 | 429 ▼ 3.0% | 401 ▼ 6.6% | 385 ▼ 4.0% | 509 ▲ 32.3% | |
195 | 226 ▲ 16.2% | 174 ▼ 23.0% | 199 ▲ 14.2% | 225 ▲ 12.9% | ||
| Gross ProfitDerived | 239 | 198 ▼ 17.4% | 219 ▲ 11.0% | 184 ▼ 16.2% | 281 ▲ 53.1% | |
| Gross Margin %Derived | 55.12% | 46.63% | 55.74% | 48.02% | 55.61% | |
131 | 137 ▲ 4.7% | 151 ▲ 10.4% | 150 ▼ 1.0% | 188 ▲ 25.8% | ||
| EBITDA (Operating Profit)Derived | 108 | 61 ▼ 44.0% | 68 ▲ 12.6% | 34 ▼ 49.8% | 93 ▲ 172.3% | |
| OPM %Derived | 24.96% | 14.30% | 17.33% | 8.94% | 18.42% | |
13 | 14 ▲ 10.5% | 32 ▲ 123.6% | 29 ▼ 9.9% | 40 ▲ 37.1% | ||
| Profit Before Tax (PBT) | 104 | 45 ▼ 57.0% | 44 ▼ 2.7% | 8 ▼ 82.6% | 57 ▲ 652.2% | |
8 | -1 ▼ 108.6% | 13 ▲ 1966.4% | 2 ▼ 85.9% | 15 ▲ 701.4% | ||
| Effective Tax %Derived | 7.92% | -1.58% | 30.33% | 24.62% | 26.23% | |
| Total Profit for Period | 96 | 45 ▼ 52.6% | 30 ▼ 33.3% | 6 ▼ 81.2% | 42 ▲ 636.1% | |
| Net Profit (Owner's PAT)Derived | 96 | 45 ▼ 52.6% | 30 ▼ 33.3% | 6 ▼ 81.2% | 42 ▲ 636.1% | |
| Net Profit Margin %Derived | 22.11% | 10.74% | 7.71% | 1.49% | 8.31% | |
| PAT Growth YoY %Derived | — | -52.56% | -33.27% | -81.18% | 636.11% | |
| Earnings Per Share (EPS ₹) | 43.25 | 20.52 ▼ 52.6% | 12.98 ▼ 36.7% | 2.44 ▼ 81.2% | 17.98 ▲ 636.9% | |
| Diluted Shares Outstanding (Cr) | 2 | 2 ▲ 0.0% | 2 ▲ 5.5% | 2 ▲ 0.0% | 2 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | -0 | 1 ▲ 546.9% | 0 ▼ 96.8% | 1 ▲ 3266.7% | 3 ▲ 355.4% | |
| Total Expenses (incl. D&A & Interest) | 338 | 385 ▲ 13.6% | 357 ▼ 7.1% | 377 ▲ 5.6% | 452 ▲ 19.9% | |
| Material Cost % of RevenueDerived | 58.69% | 50.95% | 45.43% | 45.40% | 51.94% | |
| Employee Cost % of RevenueDerived | 7.11% | 9.11% | 13.92% | 13.83% | 12.44% | |
| Other Cost % of RevenueDerived | 23.05% | 23.21% | 24.49% | 25.25% | 24.76% | |
| Interest Coverage (x)Derived | 20.71x | 6.07x | 6.52x | 5.08x | 19.75x |
Tatva Chintan Pharma Chem segment analysis : revenue and profit mix.
Disclosed business segments at Tatva Chintan Pharma Chem with their share of revenue and profit, switchable between consolidated and standalone reporting.
Tatva Chintan Pharma Chem discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Tatva Chintan Pharma Chem Ltd.
Our AI distills the core fundamental drivers supporting Tatva Chintan Pharma Chem Ltd, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Tatva Chintan Pharma Chem Ltd's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Strong promoter holding of 72.02% signals insider confidence and long-term commitment
Low debt-to-equity ratio of 0.154x ensures robust financial flexibility and stability
Operating margin of 11.13% demonstrates efficient cost management and operational discipline
Quarterly revenue growth of 24.40% indicates strong top-line momentum and market traction
Diversified customer base across automotive, pharma, agrochemicals reduces concentration risk
Key Risks.
High P/E ratio of 66.21x suggests significant overvaluation relative to earnings
Latest quarterly EPS grew 902.00% YoY, but from an extremely depressed base
ROE of 5.53% and ROCE of 7.14% fall substantially below industry peer benchmarks
Negative free cash flow of ₹426.18 Cr indicates persistent cash burn despite profitability
Dividend yield of 0.08% offers minimal income return to shareholders
Flip Conditions.
Valuation risk. a P/E above 99 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
Tatva Chintan Pharma Chem Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Tatva Chintan Pharma Chem Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Tatva Chintan Pharma Chem Ltd chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Tatva Chintan Pharma Chem Ltd — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Tatva Chintan Pharma Chem Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Tatva Chintan Pharma Chem Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Tatva Chintan Pharma Chem Ltd stood at 38.5% of traded volume, against a 20-day average of 39.2%.
Tatva Chintan Pharma Chem announcements: results, concalls, ratings, M&A.
Filings Tatva Chintan Pharma Chem sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Tatva Chintan Pharma Chem files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 129 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
Tatva Chintan Pharma Chem Limited has informed the Exchange about Schedule of meet
Analysts/Institutional Investor Meet/Con. Call Updates
Tatva Chintan Pharma Chem Limited has informed the Exchange about Schedule of meet
Analysts/Institutional Investor Meet/Con. Call Updates
Tatva Chintan Pharma Chem Limited has informed the Exchange about Schedule of meet
Analysts/Institutional Investor Meet/Con. Call Updates
Tatva Chintan Pharma Chem Limited has informed the Exchange about Schedule of meet
Analysts/Institutional Investor Meet/Con. Call Updates
Tatva Chintan Pharma Chem Limited has informed the Exchange about Transcript
Investor decks & rating reports.
Tatva Chintan Pharma Chem dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Tatva Chintan Pharma Chem has declared, sequenced by announce and record date.
Tatva Chintan Pharma Chem corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Tatva Chintan Pharma Chem Ltd: business, sector, key facts.
What Tatva Chintan Pharma Chem Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Tatva Chintan Pharma Chem Ltd operates in the Specialty Chemicals industry under the Chemicals sector, listed as NSE: TATVA, BSE: 543321.
Tatva Chintan Pharma Chem Limited (TCPL) is a prominent Indian manufacturer and supplier of specialty chemicals, catering to both domestic and international markets. Their business model centers on providing high-quality, specialized chemical compounds for a diverse range of industrial applications. This specialization distinguishes them within the broader chemical industry, allowing them to focus on niche markets and develop strong expertise in their chosen areas.
A core component of TCPL's product portfolio lies in structure-directing agents (SDAs) used in the synthesis of zeolites. Zeolites are crystalline aluminosilicate minerals with various industrial applications, and TCPL's SDAs play a crucial role in controlling the structure and properties of these materials. This demonstrates their involvement in a technologically advanced segment of the chemical industry requiring sophisticated chemical engineering and synthesis expertise.
Beyond zeolite synthesis, TCPL produces and distributes a wide array of other specialty chemicals. This includes phase-transfer catalysts, which accelerate chemical reactions; electrolyte salts for cutting-edge energy storage technologies like supercapacitors and zinc-ion batteries; and various pharmaceutical and agrochemical products. This broad product range underscores their ability to adapt to evolving market demands and serve multiple sectors.
The company's customer base spans a multitude of industries, highlighting the versatility of their chemical offerings. These include the automotive sector, refineries, pharmaceutical manufacturers, agrochemical producers, manufacturers of paints and coatings, dyes and pigments, personal care products, and companies in the flavor and fragrance industries. This widespread reach indicates the diverse applications of their specialized chemicals and their success in penetrating significant market segments.
In summary, Tatva Chintan Pharma Chem Limited operates a successful business focused on the manufacturing and sale of high-value specialty chemicals. Their expertise in specific areas, coupled with a diversified customer base and a broad product portfolio, positions them as a significant player within the global chemical industry. The company's continued focus on innovation and adaptation to emerging technological needs ensures their continued relevance and growth prospects within the market.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarti Industries (AARTIIND) Share PricePeer
- Aarti Surfactants (AARTISURF) Share PricePeer
- Archean Chemical Industries (ACI) Share PricePeer
- Aether Industries (AETHER) Share PricePeer
- Alkali Metals (ALKALI) Share PricePeer
- Stocks near 52-week high (breakout watch)Screener
- Breakout Trader strategy playbookStrategy
- Top Gainers TodayScreener
- Other overvalued NSE stocksScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Tatva Chintan Pharma Chem Ltd (TATVA).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Tatva Chintan Pharma Chem Ltd (TATVA)?
The current share price of Tatva Chintan Pharma Chem Ltd (TATVA) is ₹1,788.2. Today, the stock has gained by ₹108.00 (6.43%), trading in a range of ₹1,676.1 to ₹1,799. The stock opened at ₹1,685.5 with a trading volume of 1,79,387 shares.
02Is Tatva Chintan Pharma Chem Ltd stock a good investment for long-term?
Tatva Chintan Pharma Chem Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹4,174.31 crores, P/E ratio of 76.19, ROE of 5.53%, and ROCE of 7.14%. The dividend yield stands at 0.06%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Tatva Chintan Pharma Chem Ltd stock?
The 52-week high price of Tatva Chintan Pharma Chem Ltd (TATVA) is ₹1,835, while the 52-week low is ₹976.4. Currently trading at ₹1,788.2, the stock is 94.5% away from its 52-week low and 2.6% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Tatva Chintan Pharma Chem Ltd stock at the current price?
Whether to buy Tatva Chintan Pharma Chem Ltd stock at ₹1,788.2 depends on multiple factors. The stock is currently trading with a P/E ratio of 76.19 and P/B ratio of 5.01. Today's performance shows a gain of 6.43%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Tatva Chintan Pharma Chem Ltd and when is the next dividend?
Tatva Chintan Pharma Chem Ltd offers a dividend yield of 0.06%, which means for every ₹100 invested at the current price of ₹1,788.2, you can expect to receive approximately ₹0.06 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Tatva Chintan Pharma Chem Ltd?
Tatva Chintan Pharma Chem Ltd's key financial metrics include: P/E Ratio: 76.19, P/B Ratio: 5.01, ROE: 5.53%, ROCE: 7.14%, Dividend Yield: 0.06%, EPS: ₹22.00, Book Value: ₹334, and Debt-to-Equity: 0.15. The company's market cap stands at ₹4,174.31 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Tatva Chintan Pharma Chem Ltd stock performing today in the market?
Tatva Chintan Pharma Chem Ltd stock opened at ₹1,685.5 and is currently trading at ₹1,788.2, showing a gain of ₹108.00 (6.43%). The intraday high is ₹1,799 and low is ₹1,676.1. The trading volume stands at 1,79,387 shares, indicating moderate market participation today.
08What is the P/E ratio of Tatva Chintan Pharma Chem Ltd and what does it indicate?
Tatva Chintan Pharma Chem Ltd has a Price-to-Earnings (P/E) ratio of 76.19, which means investors are willing to pay ₹76.19 for every ₹1 of earnings. With an EPS of ₹22.00, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Tatva Chintan Pharma Chem Ltd (TATVA) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.